{"title":"Percutaneous Treatment of Mitral Valve Regurgitation: An Evolving Field","authors":"A. Sala, O. Alfieri","doi":"10.33696/cardiology.2.013","DOIUrl":"https://doi.org/10.33696/cardiology.2.013","url":null,"abstract":"Transcatheter mitral valve repair is, in fact, one of the greatest evolving fields in valvular heart interventions, with a continuous growing number of devices [7,8]. As previously underlined, the mitral valve apparatus is a complex anatomical and functional structure. Therefore, different devices have been developed capable of targeting the various components of the mitral valve: MV annulus, MV leaflets, and the subvalvular apparatus. This tries to mimic surgical mitral valve repair, either as single or combined procedures. The availability of such a widespectrum of devices allows to achieve a tailored approach for treating each patient: the right device according to the specific lesion [9].","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"280 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72419611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Beneficial Effects of Surgical Closure of Atrial Septal Defect Outweigh Potential Complications in Sick Infants","authors":"T. Tsuda, A. Bhat","doi":"10.33696/cardiology.2.011","DOIUrl":"https://doi.org/10.33696/cardiology.2.011","url":null,"abstract":"Atrial septal defect (ASD) is a common congenital heart disease diagnosed during childhood. Persistently increased pulmonary blood flow and dilated right atrium (RA) and right ventricle (RV) result in multiple symptoms and morbidities in adulthood; untreated adults may develop exercise intolerance, congestive heart failure, atrial tachyarrhythmias, pulmonary hypertension (PH), embolic stroke, or even death [1,2]. Asymptomatic children with ASD are commonly referred for elective ASD closure around 3 to 6 years of age [2,3].","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84597136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cardiac Stem Cell Therapy, Quo Vadis","authors":"Hescheler Daniel, Hescheler Jürgen","doi":"10.33696/cardiology.2.012","DOIUrl":"https://doi.org/10.33696/cardiology.2.012","url":null,"abstract":"Cardiovascular disease causes 30% of global mortality and is still the number one cause of death worldwide [1]. A main patho-physiological process is the coronary disease leading to malperfusion and ischemic cardiac disease as well as cardiac infarction. Despite the many improvements of cardiovascular therapies such as coronary stents, percutaneous transluminal coronary angioplasty (developed in 1977 [2]) or bypass surgery, scared heart tissue can still not be repaired. It seems, that finding of new therapeutic options are necessary. Hereby, cell therapy is a great hope. It is almost 30 years ago when cardiomyoplasty was proposed, i.e. culturing cardiac cells derived from stem cells and implanting them back into scar tissue. In 1991 Hescheler and Wobus [3] could show for the first time the physiological properties in cardiomyocytes developed within embryoid bodies, i.e. the first functional in vitro differentiation system of embryonic stem cells.","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82949798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"When Can a Pulmonary Embolism and Deep Vein Thrombosis Patient Fly Safely Again on Airplane? A Case Report","authors":"L. Lins, C. LinW, W. Hsun","doi":"10.26420/AUSTINJCLINCARDIOLOG.2021.1079","DOIUrl":"https://doi.org/10.26420/AUSTINJCLINCARDIOLOG.2021.1079","url":null,"abstract":"There was no recommendation in the current guidelines for how long after the pulmonary embolism (PE) attack the patient can fly again safely on an airplane. A 45 years old female was admitted to our hospital because of deep vein thrombosis and acute PE. Due to persistent leg swelling and afraid of recurrent PE for long distance flights, this patient received four weeks anticoagulant therapy before flying. Eventually, she flew back safely. This report describes our preliminary experience for managing this patient with deep vein thrombosis and PE.","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"385 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74044737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Ponti, M. Manfredini, G. Oliva, T. Ozben, Caterina Fontana, A. Tomasi
{"title":"Predicting COVID-19 Hospitalized Patients’ Outcome with Homocysteine","authors":"G. Ponti, M. Manfredini, G. Oliva, T. Ozben, Caterina Fontana, A. Tomasi","doi":"10.33696/cardiology.2.010","DOIUrl":"https://doi.org/10.33696/cardiology.2.010","url":null,"abstract":"Background: Homocysteine (Hcy) has been reported as a potential predictive biomarker for CoViD-19 infection severity in many studies. Hyper-homocysteinemia is related to many virus infection outcomes, including HEV, HPV and HIV. Recent data confirmed the value of Hcy in predicting the risk of severe pneumonia. Materials and Methods: Our retrospective cohort study, including 313 CoViD-19 hospitalized patients (female 34.8%;mean age 62 years), also included a broad panel of clinical laboratory data collected. Of the enrolled patients, 10.9% died during hospitalization (3% were transferred to other hospitals and were lost to follow-up). Results: Hcy was found to be the strongest predictor of CoViD- 19 critical-progression leading to death. Univariate analysis demonstrated that age (OR 1.04), Hcy (OR 1.06), and neutrophil/lymphocyte count ratio (OR 1.03) were significant predictors of critical progression leading to death and RBC (OR 0.68) and lymphocytes count (OR 0.23) with benign outcome. ROC analysis indicated Hcy cut off of 16 μmol/L for predicting CoViD- 19 infection outcome (sensitivity 40% and specificity 84%);patients with Hcy levels >16 μmol/L had significantly increased risk of in-hospital mortality (p=0.002) both as a continuous and dichotomic value. Conclusions: Our results demonstrate that Hcy is an effective predictive biomarker for hospitalized CoViD-19 patients' outcome. Hcy may be a valuable biomarker to help clinicians to identify patients who are at higher risk for severe CoViD-19 infection.","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90663316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carreon Am, I. Mohsin, B. Watson, Carter Rn, M. Ponder, K. Kramer
{"title":"An Unusual Case of Pannus Formation - A Late Postoperative Complication of a Prosthetic Valve Replacement Causing Severe Cardiomyopathy","authors":"Carreon Am, I. Mohsin, B. Watson, Carter Rn, M. Ponder, K. Kramer","doi":"10.26420/AUSTINJCLINCARDIOLOG.2021.1076","DOIUrl":"https://doi.org/10.26420/AUSTINJCLINCARDIOLOG.2021.1076","url":null,"abstract":"There are several well-known long-term complications following prosthetic valve replacement. Pannus formation is one of the rare complications whose estimated incidence varies between 0.3% and 1.3% per patient-year [1]. The exact etiology of pannus formation is unknown but histopathologically, pannus formation is due to fibroelastic hyperplasia that variably occurs after valve implantation [2]. The rarity and acute coronary syndrome like clinical presentation makes pannus formation a clinically important diagnosis during initial presentation. Workup preferably includes Transthoracic Echocardiography (TEE) with or without CT angiography. Management includes urgent or emergent surgical excision of the pannus with or without re-replacement of the aortic valve [1]. We present a 66-year-old female who presented with typical angina symptoms along with diffuse ischemic EKG changes five years after aortic valve replacement surgery with Trifecta Bioprosthesis due to severe aortic stenosis with Non-ST Elevation Myocardial Infarction (NSTEMI). Coronary angiography done on admission showed left main ostial stenosis of 90-95 % in proximity to the aortic valve prosthesis. A Transthoracic Echocardiogram (TTE) revealed an ejection fraction of 30-35 % with global hypokinesia but did not suggest any valve dysfunction. CT angiogram was done the next day which revealed a non-calcified plaque (pannus) greater than 75% occlusion in the left main in proximity of the aortic valve. Despite expedited care and surgical evaluation, unfortunately the patient decompensated in the surgical operating room and did not survive.","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78601606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Younes, S. Yalamanchili, H. Ali, C. Onyekwelu, A. Movahed
{"title":"Myocardial Infarction and Three-Vessel Coronary Artery Disease as Presenting Features of Granulomatosis with Polyangiitis: A Case Report with Review of Literature","authors":"A. Younes, S. Yalamanchili, H. Ali, C. Onyekwelu, A. Movahed","doi":"10.26420/AUSTINJCLINCARDIOLOG.2021.1075","DOIUrl":"https://doi.org/10.26420/AUSTINJCLINCARDIOLOG.2021.1075","url":null,"abstract":"","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86670331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sinha Santosh Kumar, Sharma Awadesh Kumar, Razi Mahmodullah, P. Umeshwar
{"title":"Innovative Technique of Primary Percutaneous Coronary Intervention in Patients with Impaired Renal Function using Ultra Low Volume Contrast Agent Using Side Branch Wire as a Marker","authors":"Sinha Santosh Kumar, Sharma Awadesh Kumar, Razi Mahmodullah, P. Umeshwar","doi":"10.23937/2378-2951/1410222","DOIUrl":"https://doi.org/10.23937/2378-2951/1410222","url":null,"abstract":"Contrast-induced nephropathy (CIN) is a serious complication in patients with chronic kidney disease with coronary artery disease who undergo percutaneous coronary intervention (PCI), and is associated with higher morbidity and mortality in short and long term. The limiting volume of contrast agent is safest and most reliable strategy to prevent CIN. Here, we report a case of suc¬cessful primary PCI using only 13 ml of contrast (iodixanol) of mid left anterior descending artery where wire in diagonal branch served as a landmark in a 75-year-old diabetic and hypertensive male who had presented with ST segment elevation anterior wall myocardial infarction and had marked renal dysfunction having serum creatinine of 3.3 mg%. There was no change in basal renal function after the procedure and safely discharged.","PeriodicalId":15510,"journal":{"name":"Journal of Clinical Cardiology","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84578458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}